Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia

Table 2

Selected clinical trials using lenalidomide in combination for treatment CLL. NR: not reported.

Study	Regimen	No. of patients	TLS all grades	TFR all grades	Hematologic side effects grade 3/4	OR (%)	CR (%)	OS (%)	PFS
Ferrajoli et al. [22] phase II; relapsed/refractory CLL	10 mg/d Lenalidomide + rituximab weekly	59	1,7%	37%	Neutropenia 68% thrombocytopenia 22% anemia 10%	64	8	NR	NR
Badoux et al. [24] phase II; relapsed/refractory CLL	10 mg/d lenalidomide + ofatumumab weekly	16	NR	13%	Neutropenia 50%; anemia 13%	63	13	NR	NR
Blum et al. [29] phase I; relapsed/refractory CLL	2.5 mg/d escalated to 25 mg/d lenalidomide + flavopiridol	15	14%	7%	Neutropenia 86% thrombocytopenia 38% anemia 38%	46	0	NR	NR
GIMEMA LLC 606 [25] phase I; relapsed/refractory CLL	2.5 mg/d escalated to 15 mg/d lenalidomide + cyclophosphamide + fludarabine	9	0	11%	Transient grade 3-4 neutropenia in the majority of pts	67	33	NR	NR
Egle et al. [27] phase; untreated CLL	2.5 mg/d escalated to 25 mg/d lenalidomide + fludarabine + rituximab	10	0	0	Neutropenia 70%	90	0	NR	NR